Login to Your Account



Santarus Partners Technology With TAP In Potential $100M Deal

By Kim Coghill


Wednesday, July 10, 2002
Santarus Inc. stands to gain up to $100 million through a licensing agreement announced Tuesday with TAP Pharmaceutical Products Inc. aimed at developing a next-generation therapy for upper gastrointestinal diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription